Novo Nordisk A/S (NYSE:NVO) Stock Price Down 2.5% – Time to Sell?

Novo Nordisk A/S (NYSE:NVO) dropped 2.5% during mid-day trading on Wednesday . The company traded as low as $37.00 and last traded at $37.4760. Approximately 25,317,597 shares were traded during trading, an increase of 1% from the average daily volume of 25,111,252 shares. The stock had previously closed at $38.43.

Novo Nordisk A/S News Summary

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: FDA approves higher‑dose Wegovy (semaglutide 7.2 mg, “Wegovy HD”) with strong STEP UP trial weight‑loss results (~20.7% mean weight loss); company plans a U.S. launch in April—this supports revenue and market share recovery vs. Lilly. Reuters: Novo Nordisk wins U.S. nod for higher-dose Wegovy
• Positive Sentiment: Chinese government official expressed support for Novo Nordisk’s continued presence and market cultivation in China—political goodwill could ease market access and reimbursement discussions in a major growth market. Reuters: China expresses hopes over Novo Nordisk’s presence in market
• Neutral Sentiment: Sanford C. Bernstein initiated coverage on NVO — could increase analyst attention and liquidity; impact depends on the firm’s stance and ratings (article linked). Sanford C. Bernstein Initiates Coverage on Novo Nordisk
• Neutral Sentiment: Rhythm Pharmaceuticals won an FDA approval for a rare genetic‑obesity therapy—limited overlap with Novo’s mass‑market GLP‑1 franchise, so competitive impact is minimal. Yahoo/Finance: Rhythm Grabs A New Obesity Approval
• Negative Sentiment: An FDA warning letter flagged deficiencies in Novo’s pharmacovigilance reporting for serious/unexpected adverse events for GLP‑1s (including Ozempic/Wegovy)—this raises regulatory scrutiny and potential compliance costs, which investors view negatively. Yahoo/Finance: FDA Letter Puts Novo Nordisk GLP-1 Risks And Valuation In Focus
• Negative Sentiment: Patent expiry for semaglutide in India opens the market to low‑cost generics (reports of Ozempic copies selling for ~$14) — this threatens international pricing and volume, particularly in large emerging markets. Financial Post: Ozempic Copies to Cost $14 in India
• Negative Sentiment: Competitive pressure from Eli Lilly’s next‑gen agents (retatrutide) and positive data for rivals are keeping investor concerns about market share and pricing intensity elevated. ProactiveInvestors: Lilly GLP-1 trial data and concerns
• Negative Sentiment: Semaglutide failed to show benefit in early Alzheimer’s at AD/PD 2026—this is a setback for potential label expansion beyond metabolic indications and reduces upside from new indications. Yahoo News: AD/PD 2026: semaglutide fails in early Alzheimer’s

Analyst Upgrades and Downgrades

Several research analysts have weighed in on NVO shares. Citigroup assumed coverage on shares of Novo Nordisk A/S in a report on Tuesday, January 27th. They issued a “neutral” rating on the stock. Zacks Research upgraded Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 10th. Weiss Ratings downgraded Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday. Kepler Capital Markets cut Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Tuesday, February 24th. Finally, JPMorgan Chase & Co. restated a “neutral” rating on shares of Novo Nordisk A/S in a research note on Tuesday, February 24th. Four investment analysts have rated the stock with a Buy rating, eighteen have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $65.56.

Novo Nordisk A/S Stock Down 1.5%

The company has a current ratio of 0.80, a quick ratio of 0.57 and a debt-to-equity ratio of 0.61. The firm has a market cap of $163.00 billion, a price-to-earnings ratio of 10.52 and a beta of 0.73. The firm’s 50 day simple moving average is $48.67 and its two-hundred day simple moving average is $51.29.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.90 by $0.11. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. The firm had revenue of $12.43 billion for the quarter, compared to analyst estimates of $11.97 billion. On average, equities analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Dividend Announcement

The business also recently declared a dividend, which will be paid on Wednesday, April 8th. Investors of record on Monday, March 30th will be given a dividend of $1.2751 per share. The ex-dividend date of this dividend is Monday, March 30th. This represents a yield of 541.0%. Novo Nordisk A/S’s dividend payout ratio is currently 23.63%.

Hedge Funds Weigh In On Novo Nordisk A/S

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Rockefeller Capital Management L.P. lifted its position in Novo Nordisk A/S by 77.2% during the fourth quarter. Rockefeller Capital Management L.P. now owns 1,340,858 shares of the company’s stock worth $68,223,000 after purchasing an additional 584,275 shares during the period. Larry Mathis Financial Planning LLC bought a new position in Novo Nordisk A/S in the 4th quarter valued at about $535,000. PeakShares LLC bought a new position in Novo Nordisk A/S in the 4th quarter valued at about $491,000. Union Savings Bank acquired a new position in shares of Novo Nordisk A/S in the 4th quarter valued at approximately $312,000. Finally, Mengis Capital Management Inc. lifted its holdings in shares of Novo Nordisk A/S by 303.2% during the 4th quarter. Mengis Capital Management Inc. now owns 66,694 shares of the company’s stock worth $3,393,000 after acquiring an additional 50,154 shares during the period. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.